Splash Beverage Q2 loss narrows 64% to ~$4M; rebranding as Endovia Health Sciences

SPLASH BEVERAGE GROUP, INC.

H1 2026 loss from continuing ops ~$4M vs ~$11M in H1 2025, improvement of ~$7M (64%).
In early July 2026, entered exclusive global license for CannEpil®, a pharma-grade cannabinoid platform for drug-resistant epilepsy.
On Jul 31 2026, signed development agreement with Lupvindol Biosciences to advance CannEpil® veterinary product through FDA INAD and Conditional Approval.
Rebrand to Endovia Health Sciences with name and ticker change effective on NYSE American Aug 24, 2026.
Preparing to relaunch CannEpil® in UK, Ireland and select Latin American markets through existing distribution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.